Peptide lab results and clinical outcomes
A result becomes more interesting when the neighboring entries stop agreeing with it.
Results beside their complications
A metabolic winner would be a convenient answer. I see incompatible clinical questions across these studies. The clinically relevant question changes from one row to the next, and so does the reason for caution.
| Compound | Observation | Accompanying question |
|---|---|---|
| MOTS-c | Higher blood levels accompanied greater death or cardiovascular-event risk in dialysis | The cohort measured endogenous peptide. What would a human treatment trial find? |
| Semaglutide | Cardiovascular events fell in SELECT and major kidney outcomes fell in FLOW | The safety review raises the eye concern with rapid glucose correction in people with existing diabetic retinopathy. |
| Retatrutide | Triglyceride and insulin-resistance markers improved | The obesity trial also recorded a dose-related resting-heart-rate increase. Longer-term significance remains open. |
| Tesamorelin | Visceral and liver fat fell in HIV-associated lipodystrophy trials | Growth hormone and IGF-1 rise; long-term hormonal safety remains a separate question. |
The entries concern different populations and research designs. The MOTS-c row is observational; the other rows include human treatment trials. Their placement together is an invitation to inspect the differences.
Where events were counted
The SELECT cardiovascular result came from adults with established cardiovascular disease and overweight or obesity, without diabetes. The FLOW kidney result came from adults with type 2 diabetes and chronic kidney disease. Their combined endpoints included serious illness and death, with different definitions.
That gives semaglutide the firmest direct serious-illness evidence among these four compounds in this journal. It leaves room for digestive harms, gallbladder disease and specific safety concerns. A strong efficacy finding can coexist with an important safety qualification.
Retatrutide’s weight and liver-fat trials and tesamorelin’s body-composition trials measured valuable changes without resolving comparable long-term outcome questions. MOTS-c’s mouse performance findings remain experiments in mice. I distrust the favorable measurement drafted to answer a different clinical question.
Approved uses and individual decisions
Semaglutide is an approved prescription medicine for particular uses. Tesamorelin’s approved use concerns excess abdominal fat in adults with HIV-associated lipodystrophy. Retatrutide remains investigational, and MOTS-c has no FDA-approved human use in these sources.
Those distinctions affect the clinical setting in which evidence can be applied. Personal care also depends on existing illnesses, medicines and an individual assessment. A collection of papers cannot provide that assessment. The reading list provides the underlying studies for a closer look.